P. Bonomi

L. Morrison, J. Coon, V. Villaflor, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).

M. Socinski, Bruce E. Johnson, R. Govindan, 2017, Lung cancer.

Positron emission tomography demonstrates radiation-induced changes to nonirradiated lungs in lung cancer patients treated with radiation and chemotherapy.

Atif J. Khan, P. Bonomi, Amjad Ali, 2005, Chest.

Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.

J. Borgia, C. Wakefield, P. Bonomi, 2021, Journal of immunological methods.

Treatment of locally advanced non-small cell lung cancer.

P. Bonomi, A. Kim, M. Fidler, 1993, Clinical advances in hematology & oncology : H&O.

E-10. Chemoradiation for stage III non-small cell lung cancer

P. Bonomi, 2003 .

Chemoradiation in locally advanced non-small cell lung cancer.

P. Bonomi, W. Shirazi, 2001, Cancer treatment and research.

Combined modality treatment using BID radiation for locally advanced non‐small cell lung carcinoma

S. Taylor, W. Warren, P. Bonomi, 1994, Cancer.

Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Sm

M. Socinski, R. Govindan, R. Hermann, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung C

C. Obasaju, M. Socinski, R. Govindan, 2015, Clinical lung cancer.

Randomized Phase II Study of Cetuximab and Bevacizumab in Combination with Two Regimens of Paclitaxel and Carboplatin in Chemonaive Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

H. Youssoufian, M. Min, P. Bonomi, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.

R. Herbst, J. Heymach, F. D. De Braud, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.

P. Disaia, P. Bonomi, J. Blessing, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of 29 patients with bulky squamous cell carcinoma of the cervix with simultaneous cisplatin, 5-fluorouracil, and split-course hyperfractionated radiation therapy☆

Anna M. Miller, C. Kirschner, E. Yordan, 1990 .

Historic evidence and future directions in clinical trial therapy of solid tumors.

J. Gollob, P. Bonomi, 2006, Oncology.

Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients.

M. Liptay, W. Warren, P. Bonomi, 2011, The Annals of thoracic surgery.

Neoadjuvant chemoradiation therapy in non-small cell lung cancer: the Rush University experience

P. Bonomi, L. Faber, 1993 .

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.

A. Rademaker, E. Hart, T. Hensing, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Potential Predictive Value of Cyclooxygenase-2 Expression and Increased Risk of Gastrointestinal Hemorrhage in Advanced Non–Small Cell Lung Cancer Patients Treated with Erlotinib and Celecoxib

A. Argiris, J. Coon, V. Villaflor, 2008, Clinical Cancer Research.

Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer.

P. Gattuso, M. Liptay, W. Warren, 2011, Lung cancer.

Serum-free estradiol (E2) levels are prognostic in men with chemotherapy-naive advanced non-small cell lung cancer (NSCLC) and performance status (PS) 2

J. Singer, P. Bonomi, F. Oldham, 2007 .

P-611 Final results from a phase II study of erlotinib (TarcevaTM) monotherapy in patients with advanced non-small cell lung cancer following failure of platinum-based chemotherapy

J. Rigas, R. Perez-soler, G. Clark, 2003 .

A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC).

N. Hanna, R. Govindan, T. Lynch, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Communication Differences Between Physicians and Their Patients in an Oncology Setting

D. Cella, P. Bonomi, T. Sher, 2004, Journal of Clinical Psychology in Medical Settings.

Prognostic Significance of Skeletal Muscle Loss During Early Postoperative Period in Elderly Patients with Esophageal Cancer

P. Shah, J. Borgia, P. Bonomi, 2019, Annals of Surgical Oncology.

Eastern Cooperative Oncology Group experience with chemotherapy in advanced non-small cell lung cancer.

P. Bonomi, 1998, Chest.

Treatment of locally advanced non-small cell lung cancer.

P. Bonomi, A. Kim, M. Fidler, 1993, Clinical advances in hematology & oncology : H&O.

Combined modality therapy for locally advanced non‐small cell lung carcinoma

K. Rowland, S. Taylor, C. Kittle, 1990, Cancer.

Neoadjuvant treatment in locally advanced non-small cell lung cancer.

P. Bonomi, L. Faber, 1990, Seminars in surgical oncology.

Preoperative combined modality therapy for stage III M0 non-small cell lung carcinoma.

K. Rowland, S. Taylor, C. Kittle, 1987, International journal of radiation oncology, biology, physics.

Qualitative analysis of coomassie‐blue‐stained proteins from normal prostate, benign prostatic hypertrophy, or adenocarcinoma of the prostate, separated by two‐dimensional protein electrophoresis

P. Bonomi, J. Baranowski, S. Economou, 1985 .

Provisional “Normograms” for identifying adenocarcinomas of the prostate or colon and hepatocellular carcinoma derived from their distribution of proteins separated by two‐dimensional electrophoresis

P. Bonomi, J. Baranowski, S. Economou, 1983, The Prostate.

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive‐Stage Small Cell Lung Cancer (SCLC)

A. Wozniak, B. Halmos, S. Gadgeel, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference

M. Socinski, R. Govindan, Kwok-Kin Wong, 2007, Clinical Cancer Research.

A ten year experience with hepatic resection.

D. Roseman, A. Straus, P. Bonomi, 1984, Surgery, gynecology & obstetrics.

Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter?

M. Liptay, W. Warren, P. Bonomi, 2009, The Annals of thoracic surgery.

Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaïve pts with advanced NSCLC and poor performance status (PS2).

M. Socinski, K. O'Byrne, L. Paz-Ares, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients

J. Borgia, M. Pool, P. Bonomi, 2018, BMC Cancer.

Associations between sinus tachycardia and adverse cardiovascular outcomes and mortality in cancer patients

P. Bonomi, P. Bhatt, Ibtihaj Fughhi, 2021, Journal of thoracic disease.

Phase II Trial of Acivicin Versus Etoposide‐Cisplatin in Non‐Small Cell Lung Cancer: An Eastern Cooperative Oncology Group Study

D. Finkelstein, P. Bonomi, A. Chang, 1994, American journal of clinical oncology.

Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) treatment of non-oat cell bronchogenic carcinoma.

J. Wolter, N. Vogelzang, P. Bonomi, 1978, Cancer treatment reports.

Carboplatin in non-small cell lung cancer: review of the Eastern Cooperative Oncology Group trial and comparison with other carboplatin trials.

P. Bonomi, 1991, Seminars in oncology.

Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response.

D. Ettinger, J. Bertino, R. Creech, 1986, Seminars in oncology.

Neuroendocrine carcinomas of the colon and rectum: a clinicopathologic evaluation.

W. Warren, D. Roseman, P. Bonomi, 1988, Surgery.

Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.

J. Minna, G. Scagliotti, R. Govindan, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Pilot Study of the Functional Living Index‐Cancer (FLIC) Scale for the Assessment of Quality of Life for Metastatic Lung Cancer Patients: An Eastern Cooperative Oncology Group Study

D. Finkelstein, J. Wolter, B. Cassileth, 1988, American journal of clinical oncology.

Four-Phase, Definitive Chemoradiation for a Real-World (Poor Risk and/or Elderly) Patient Population With Locally Advanced Non-small Cell Lung Cancer

P. Bonomi, M. Fidler, M. Jelínek, 2022, Cureus.

Concurrent chemotherapy and thoracic irradiation in non-small cell lung cancer.

P. Bonomi, L. Faber, S. Reddy, 1990, Hematology/oncology clinics of North America.

Recent advances with chemotherapy for NSCLC: the ECOG experience. Eastern Cooperative Oncology Group.

D. Ettinger, D. Johnson, P. Bonomi, 1998, Oncology.

Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)

C. Obasaju, E. Hart, T. Hensing, 2008 .

O-106 A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC)

P. Jänne, N. Hanna, R. Govindan, 2005 .

Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy

J. Borgia, P. Bonomi, S. Rouhani, 2021, Cancers.

Whole brain radiation therapy (WBRT) with or without oral topotecan (TPT) in patients (pts) with non-small cell lung cancer (NSCLC) with brain metastases: Final analysis of an open-label phase III study.

R. Ramlau, J. Jassem, P. Chabot, 2013 .

Metastatic breast cancer: preliminary results with oral hormonal therapy.

J. Bertino, R. Creech, J. Carpenter, 1985, Seminars in oncology.

Neuroendocrine carcinoma of the cervix: implications for staging and therapy.

R. Pazdur, G. Wilbanks, P. Bonomi, 1981, Gynecologic oncology.

Cisplatin/etoposide vs paclitaxel/cisplatin/G-CSF vs paclitaxel/cisplatin in non-small-cell lung cancer.

P. Bonomi, D. Johnson, K. Kim, 1997, Oncology.

communications to the editorSalvage Chemotherapy for Recurrent Invasive Thymoma

P. Lara, P. Bonomi, L. Faber, 1997 .

Retreatment of recurrent invasive thymoma with platinum, doxorubicin, and cyclophosphamide.

P. Lara, P. Bonomi, L. Faber, 1996, Chest.

EST 2582 Phase II Trial of Cisplatin in Metastatic or Recurrent Thymoma

D. Ettinger, D. Finkelstein, P. Bonomi, 1993, American journal of clinical oncology.

Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study.

D. Ettinger, D. Finkelstein, P. Bonomi, 1992, Journal of the National Cancer Institute.

Simultaneous cisplatin fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III, non-small cell lung cancer.

D. Mathisen, S. Taylor, C. Kittle, 1987, The Annals of thoracic surgery.

Combined modality therapy for stage III non-small cell lung carcinoma: results of treatment and patterns of failure.

S. Taylor, C. Kittle, P. Bonomi, 1992, International journal of radiation oncology, biology, physics.

Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.

G. Wilbanks, P. Bonomi, R. Slayton, 1979, Cancer treatment reports.

Vindesine: Phase II evaluation in colon cancer and description of its platelet stimulating activity

R. Pazdur, J. Wolter, A. Rossof, 2004, Cancer Chemotherapy and Pharmacology.

Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy.

P. Bonomi, M. Meriggioli, R. Malik, 2017, Journal of neuromuscular diseases.

Management of carcinoid syndrome.

J. Wolter, P. Bonomi, R. Slayton, 1979, Medical and pediatric oncology.

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.

J. Rigas, R. Perez-soler, G. Clark, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hormone receptor studies in axillary metastases from occult breast cancers

T. Saclarides, P. Bonomi, T. Witt, 1987, Cancer.

O-263 Randomized 3-arm phase II study of paclitaxel (T), carboplatin (C), and thoracic radiation (TRT) for patients with stage III non-small cell lung cancer (NSCLC). Report of locally advanced multimodality protocol (LAMP) - ACR 427

W. Curran, H. Choy, P. Bonomi, 2003 .

Elevated creatine phosphokinase MB in a patient with neuroendocrine carcinoma of the colon—Evidence for a tumor marker

D. Roseman, P. Bonomi, Inchul Lee, 1988, Diseases of the colon and rectum.

Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin.

M. Jiroutek, S. Baker, E. Rowinsky, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

72 Multicenter trial of docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): Confirmation of prolonged survival☆

Michael R. Green, D. Carbone, D. Gandara, 1997 .

Development of bead based multiplexed immunoassay for evaluation of midkine, syndecan-1, and ANGPTL4 in patient serum

J. Borgia, M. Liptay, M. Pool, 2018, Journal of immunoassay & immunochemistry.

What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592.

D. Cella, D. Fairclough, D. Eton, 2002, Journal of clinical epidemiology.

Concomitant therapy with infusion of cisplatin and 5-fluorouracil plus radiation in stage III non-small cell lung cancer.

D. Mathisen, S. Taylor, P. Bonomi, 1988, NCI monographs : a publication of the National Cancer Institute.

Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer.

J. Wolter, P. Bonomi, J. Harris, 1985, Seminars in oncology.

Review of selected randomized trials in small cell lung cancer.

P. Bonomi, 1998, Seminars in oncology.

Phase II trial of etoposide, cisplatin, continuous infusion 5-fluorouracil, and simultaneous split-course radiation therapy in stage III non-small-cell bronchogenic carcinoma.

K. Rowland, S. Taylor, W. Warren, 1986, Seminars in oncology.

Multicenter Trial of EC145 in Advanced, Folate-Receptor Positive Adenocarcinoma of the Lung

M. Edelman, B. Conley, R. Messmann, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Megestrol acetate: first-line therapy for advanced breast cancer.

J. Wolter, P. Bonomi, S. Economou, 1986, Seminars in oncology.

Primary hormonal therapy of advanced breast cancer with megestrol acetate: predictive value of estrogen receptor and progesterone receptor levels.

J. Wolter, W. Shorey, D. Roseman, 1985, Seminars in oncology.

Dosimetric uncertainties of three‐dimensional dose reconstruction from two‐dimensional data in a multi‐institutional study

W. Curran, H. Choy, G. Starkschall, 2004, Journal of applied clinical medical physics.

A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial.

Samuel J. Taylor, J. Kirkwood, J. Harris, 1985, Cancer research.

Postoperative bronchopulmonary complications in stage III lung cancer patients treated with preoperative paclitaxel-containing chemotherapy and concurrent radiation.

D. Recine, M. Sharma, P. Bonomi, 1997, Seminars in oncology.

Continuous Infusion VP-16, Bolus Cisplatin, and Simultaneous Radiation Therapy as Salvage Therapy in Small Cell Bronchogenic Carcinoma

K. Rowland, P. Bonomi, S. Reddy, 1986 .

Remission of invasive thymoma due to chemotherapy. Two patients treated with cyclophosphamide, doxorubicin, and vincristine.

S. Goldman, P. Loehrer, P. Bonomi, 1985, Chest.

Phase II randomized trial of irinotecan/docetaxel (ID) or irinotecan/gemcitabine (IG) with or without celecoxib (CBX) in 2nd-line treatment of non-small-cell lung cancer (NSCLC).

M. Socinski, L. Hart, R. Lilenbaum, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer

W. Guo, M. Socinski, Kwok-Kin Wong, 2013, Clinical Cancer Research.

Erlotinib: a new therapeutic approach for non-small cell lung cancer

P. Bonomi, 2003, Expert opinion on investigational drugs.

Comprehensive molecular profiling of lung adenocarcinoma

Steven J. M. Jones, Christopher A. Miller, Joshua M. Stuart, 2014, Nature.

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.

M. Mino‐Kenudson, J. Neal, H. Wakelee, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

L. Bubendorf, R. Stahel, S. Peters, 2018, Clinical Cancer Research.

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.

Edward S. Kim, C. Obasaju, M. Socinski, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

Edward S. Kim, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treatment of Stage IV Non-Small Cell Lung Cancer

P. Bonomi, L. DiNunno, 2002 .

Molecular and Immune Biomarker Testing in Squamous‐Cell Lung Cancer: Effect of Current and Future Therapies and Technologies

Edward S. Kim, C. Obasaju, M. Socinski, 2018, Clinical lung cancer.

Clinicopathologic Features of Advanced Squamous NSCLC.

Edward S. Kim, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinician Perspectives on Current Issues in Lung Cancer Drug Development

P. Jänne, R. Govindan, R. Herbst, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.

C. Obasaju, M. Socinski, R. Govindan, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

G. Giaccone, C. Rudin, M. Ranson, 2012, Clinical Cancer Research.

Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells

J. Borgia, P. Bonomi, J. Plate, 2013, Molecular Cancer.

Comprehensive molecular profiling of lung adenocarcinoma

Steven J. M. Jones, Christopher A. Miller, Joshua M. Stuart, 2014, Nature.

Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy

J. Borgia, M. Pool, W. Lie, 2017, Oncotarget.

Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non‐small cell lung cancer with circulating autoantibody biomarkers

J. Coon, J. Borgia, M. Liptay, 2011, International journal of cancer.

Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer

P. Bonomi, M. Fidler, M. Batus, 2010, Expert review of anticancer therapy.

Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors

J. Coon, P. Bonomi, L. Buckingham, 2007, Clinical Cancer Research.

Treatment of advanced squamous cell carcinoma of the lung: a review.

P. Bonomi, M. Fidler, M. Batus, 2015, Translational lung cancer research.

Novel treatments in non-small cell lung cancer.

P. Bonomi, W. Leslie, 2004, Hematology/oncology clinics of North America.

Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.

P. Bonomi, 2003, Lung cancer.

Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592.

D. Cella, D. Fairclough, D. Eton, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.

R. Herbst, L. Hart, D. Ramies, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin/etoposide/radiation plus escalating doses of paclitaxel in stage III non-small cell lung cancer: a preliminary report.

D. Recine, P. Bonomi, L. Faber, 1995, Seminars in oncology.

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.

M. Socinski, M. Edelman, J. Vansteenkiste, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically De fi ned Advanced Non – Small Cell Lung Cancer

M. Socinski, Kwok-Kin Wong, L. Sequist, 2013 .

Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument.

D. Tulsky, D. Cella, A. Bonomi, 1995, Lung cancer.

Multicenter phase II trial of docetaxel and carboplatin in patients with stage M B and IV non-small-cell lung cancer

J. Luketich, A. Einzig, P. Bonomi, 2005 .

Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer.

J. Luketich, A. Einzig, P. Bonomi, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria

L. Krug, C. Langer, G. Blumenthal, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

M. Jiroutek, D. Cella, D. Fairclough, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized Phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma

J. Stewart, P. Bonomi, D. Karp, 1998, Cancer.

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.

D. Finkelstein, R. Hahn, D. Tormey, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer.

J. Coon, P. Bonomi, S. Basu, 2012, Anticancer research.

Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data.

J. Schiller, R. Xu, P. Bonomi, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586).

J. Kirkwood, J. Glick, J. Schiller, 1999, Lung cancer.

Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial.

D. Carbone, D. Gandara, E. Vokes, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung cancer: new developments point the way to reduced mortality.

P. Bonomi, 2011, Oncology.

Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).

O. Kucuk, K. Pandya, P. Bonomi, 2000, American journal of clinical oncology.

Therapeutic advances in second-line treatment of advanced non-small-cell lung cancer.

P. Bonomi, 2004, Clinical lung cancer.

MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials.

M. Bonetti, A. Benson, G. Sledge, 2004, European journal of cancer.

Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.

David Cella, J. Manola, D. Cella, 2002, Journal of the National Cancer Institute.

Novel approaches for the treatment of non-small cell lung cancer.

P. Bonomi, 2001, Seminars in oncology.

Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials.

D. Cella, D. Fairclough, P. Bonomi, 1998, Statistics in medicine.

A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC): Final results

P. Jänne, N. Hanna, R. Govindan, 2005 .

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

P. Jänne, N. Hanna, R. Govindan, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

T. Choueiri, R. Heist, M. Sznol, 2019, Cancer discovery.

Mediastinal Tumors

D. Wood, L. Delbridge, S. Petersdorf, 1995, Medical Radiology.

A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.

P. Disaia, P. Bonomi, H. Ball, 1989, Gynecologic oncology.

Other compounds and targets in non-small cell lung cancer.

V. Villaflor, P. Bonomi, 2005, Seminars in oncology.

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials

M. Socinski, K. O'Byrne, J. Singer, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer

P. Bonomi, 2007, Expert review of anticancer therapy.

Implications of key trials in advanced nonsmall cell lung cancer

P. Bonomi, 2010, Cancer.

Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC).

R. Abrams, S. Shott, Atif J. Khan, 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung

T. Hensing, K. Shirai, G. Simon, 2014, Oncoscience.

Activity of ZD0473 in small-cell lung cancer: an update in patients relapsing after one prior chemotherapy regimen

J. Schiller, P. Bonomi, M. Modiano, 2001 .

P-460 Results of a phase 2 trial of HGS-ETR1 (agonistic humanmonoclonal antibody to TRAIL receptor 1) in subjects with relapsedlrecurrent non-small cell lung cancer (NSCLC)

K. Kelly, J. Crawford, Y. Oh, 2005 .

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.

K. Kelly, J. Crawford, Y. Oh, 2008, Lung cancer.

Establishment of a Multi-Analyte Serum Biomarker Panel to Identify Lymph Node Metastases in Non-small Cell Lung Cancer

Sanjib Basu, Cristina Fhied, J. Coon, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Practical and theoretical implications of weight gain in advanced non-small cell lung cancer patients.

J. Borgia, P. Bonomi, M. Fidler, 2017, Annals of translational medicine.

CDKN2A (p16) Promoter Hypermethylation Influences the Outcome in Young Lung Cancer Patients

P. Gattuso, M. Liptay, M. Pool, 2012, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

PTEN, RASSF1 and DAPK site‐specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients

J. Coon, M. Liptay, K. Walters, 2010, International journal of cancer.

Hypertrophic osteoarthropathy associated with endometrial carcinoma.

J. Margolick, E. Yordan, G. Wilbanks, 1982, Gynecologic oncology.

Doxorubicin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck.

H. Lerner, P. Bonomi, J. Showel, 1984, Cancer treatment reports.

Progesterone receptor level as a predictor of response to megestrol acetate in advanced breast cancer: a retrospective study.

J. Wolter, A. Rossof, P. Bonomi, 1983, Cancer treatment reports.

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

T. Choueiri, R. Heist, M. Sznol, 2019 .

Response to megestrol in male breast carcinoma.

P. Bonomi, K. Anderson, R. Mitsuyasu, 1981, Archives of internal medicine.

Comparison of dextran-coated charcoal and sucrose density gradient analyses of estrogen and progesterone receptors in human breast cancer.

P. Bonomi, S. Economou, K. Anderson, 1980, Cancer research.

Renal failure from metastatic breast carcinoma reversed by radiotherapy and chemotherapy.

H. Corwin, P. Bonomi, D. Pessis, 1984, Archives of internal medicine.

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

L. Freitag, J. von Pawel, U. Gatzemeier, 2008, British Journal of Cancer.

Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.

D. Ettinger, D. Neuberg, A. Wolff, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2, randomized, open‐label study of ramucirumab in combination with first‐line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer

R. Doebele, S. Verma, D. Camidge, 2015, Cancer.

Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer.

P. Bonomi, 2002, Seminars in oncology.

Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV

C. Obasaju, M. Socinski, R. Govindan, 2009, Clinical lung cancer.

An open label phase II trial of the Plk1 inhibitor BI 2536, in patients with sensitive relapse small cell lung cancer (SCLC).

M. Socinski, R. Govindan, B. Johnson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients

P. Shah, J. Borgia, P. Bonomi, 2019, Cancers.

Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale

S. O’Mahony, P. Bonomi, M. Fidler, 2016, The American journal of hospice & palliative care.

Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients.

G. Scagliotti, J. R. Pereira, W. John, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival.

R. Abrams, M. Liptay, W. Warren, 2011, International journal of radiation oncology, biology, physics.

Neuroendocrine small cell carcinomas in miscellaneous primary sites: implications for staging and therapy.

E. Yordan, R. Pazdur, L. Holinger, 1981, Anticancer Research.

Preoperative radiation therapy in regionally localized stage III non-small cell lung carcinoma: long-term results and patterns of failure.

S. Taylor, P. Bonomi, L. Faber, 1990, International journal of radiation oncology, biology, physics.

Fadrozole HCL (CGS‐16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials

A. Buzdar, P. Bonomi, A. Keller, 1996, Cancer.

Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients

R. Abrams, M. Liptay, W. Warren, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer.

D. Sher, M. Liptay, W. Warren, 2013, Clinical lung cancer.

Phase II trial of therapy with etoposide, 5-fluorouracil by continuous infusion, cisplatin, and simultaneous split-course radiation in stage III non-small cell bronchogenic carcinoma.

K. Rowland, S. Taylor, C. Kittle, 1988, NCI monographs : a publication of the National Cancer Institute.

Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0–2) Non–Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response

D. Sher, G. Chmielewski, M. Liptay, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis

A. Argento, R. C. McDonald, J. Grigorieva, 2020, Current medical research and opinion.

Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls

J. Borgia, P. Bonomi, Mary Jo Fidler, 2012, Therapeutic advances in medical oncology.

Megestrol acetate as primary hormonal therapy for advanced breast cancer.

J. V. Von Roenn, J. Wolter, H. Muss, 1988, Seminars in oncology.

Cancer Therapy : Clinical Phase II Study of Single-Agent Navitoclax ( ABT-263 ) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

G. Giaccone, C. Rudin, G. Shapiro, 2012 .

Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.

C. Obasaju, D. Mintzer, Z. Ye, 2006, Lung cancer.

Advanced age alone does not compromise outcome in fit non-small cell lung cancer (NSCLC) patients (pts) receiving platinum (DDP)-based therapy (Tx): Implications of ECOG 5592

J. Manola, Douglas B. Johnson, C. Langer, 2000 .

Long-term follow-up of patients with locally advanced or metastatic thymic malignancies: The Eastern Cooperative Oncology Group (ECOG) experience.

R. Livingston, C. Langer, M. Green, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial adriamycin and cis-dichlorodiammineplatinum(II) in squamous cell, ovarian, and testicular carcinomas.

J. Wolter, P. Bonomi, R. Slayton, 1978, Cancer treatment reports.

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.

Lucio Crino, Roger B Cohen, P. Jänne, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary results

E. Hart, T. Hensing, J. Patel, 2007 .

Role of erlotinib in the treatment of advanced non-small-cell lung cancer patients with EGFR wild-type tumors

P. Bonomi, E. Braun, 2014 .

Epidermal growth factor receptor pathway.

P. Bonomi, Philip Bonomi, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2.

M. Socinski, K. O'Byrne, K. Albain, 2006, Clinical lung cancer.

Treatment of soft tissue sarcoma with fibroblast interferon (beta-interferon): an American Cancer Society/Illinois Cancer Council Study.

N. Vogelzang, G. Locker, P. Bonomi, 1986, Cancer treatment reports.

Mitomycin C, methyl-CCNU and 5-fluorouracil in the treatment of metastatic colorectal carcinoma

A. Rossof, P. Bonomi, D. Klaassen, 2004, Cancer Chemotherapy and Pharmacology.

Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).

L. Bubendorf, R. Stahel, S. Peters, 2017 .

Modulation of the epithelial-to-mesenchymal-like transition by BMP7 and TGF-{beta} in non-small cell lung cancer cell lines in vitro.

J. Coon, J. Borgia, M. Liptay, 2010 .

Neuroendocrine carcinomas of the gastrointestinal tract.

G. Chejfec, P. Bonomi, V. Gould, 1984, Seminars in diagnostic pathology.

The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial

C. Schumann, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Analysis of prognostic factors in patients with advanced relapsed/refractory NSCLC: Cox regression analysis of a randomized phase III trial comparing docetaxel and paclitaxel poliglumex (PPX).

M. Socinski, K. O'Byrne, L. Paz-Ares, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer.

B. Mahon, J. Coon, J. Borgia, 2011, The Annals of thoracic surgery.

Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy

J. Borgia, M. Pool, W. Lie, 2017, Oncotarget.

Neutrophil to lymphocyte ratio as predictive of prolonged progression free survival (PFS) and overall survival (OS) in patients with metastatic non-small cell lung cancer (NSCLC) treated with second-line PD-1 immune checkpoint inhibitors.

J. Borgia, P. Bonomi, S. Basu, 2017 .

Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.

K. Kiel, D. Sher, P. Bonomi, 2014, Practical radiation oncology.

EGFR mutations and pAKT expression as potential predictors of gefitinib efficacy in non-small cell lung cancer (NSCLC) patients (pts)

J. Coon, V. Villaflor, A. Mauer, 2005 .

Cachexia Index utilization in patients with non-small cell lung cancer.

P. Shah, J. Borgia, A. Dudek, 2016 .

The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients

J. Borgia, M. Pool, P. Bonomi, 2018, BMC cancer.

Patterns of regional failure in stage III non-small cell lung cancer treated with neoadjuvant chemoradiation therapy and resection.

D. Sher, M. Liptay, W. Warren, 2013, Practical radiation oncology.

Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non–Small Cell Lung Cancer

K. Kiel, D. Sher, P. Bonomi, 2015, American journal of clinical oncology.

A Phase II Trial of Denileukin Diftitox in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

J. Hainsworth, J. Crawford, R. Shukla, 2009, American journal of clinical oncology.

ZD0473 treatment in lung cancer: an overview of the clinical trial results.

E. Lemarié, M. Edelman, R. Ramlau, 2002, European journal of cancer.

Platinum/etoposide therapy in non-small cell lung cancer.

P. Bonomi, 1992, Oncology.

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).

J. S. Lee, D. R. Berry, G. Giaccone, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Brief overview of combination chemotherapy in non-small-cell lung cancer.

P. Bonomi, 1986, Seminars in oncology.

387 Pulmonary complications following preoperative radiation therapy and simultaneous taxol containing chemotherapy in stage III non-small cell lung cancer (NSCLC)

W. Warren, D. Recine, M. Sharma, 1997 .

A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC).

C. Rudin, D. Camidge, L. Gandhi, 2010 .

Treatment of stage D prostatic carcinoma with megestrol acetate

J. Wolter, P. Bonomi, J. Showel, 1982, Journal of Surgical Oncology.

Cancer cachexia impact on chemotherapy dose reduction, treatment discontinuation, and survival: A qualitative systematic review.

D. Currow, P. Bonomi, R. Skipworth, 2022, Journal of Clinical Oncology.

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

Edward S. Kim, C. Obasaju, M. Socinski, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PTEN, RASSF1 and DAPK site‐specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients

J. Coon, M. Liptay, K. Walters, 2010, International journal of cancer.

Review of paclitaxel/carboplatin in advanced non-small cell lung cancer.

P. Bonomi, 1999, Seminars in oncology.

Treatment of Stage IV Non-Small Cell Lung Cancer

P. Bonomi, L. DiNunno, 2002 .

Stabilization of human breast cancer progesterone (5020) receptor by sodium molybdate.

P. Bonomi, S. Economou, K. Anderson, 1980, Clinica chimica acta; international journal of clinical chemistry.

Sequential hormone therapy for advanced breast cancer.

J. V. Von Roenn, J. Wolter, P. Bonomi, 1988, Seminars in oncology.

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

Edward S. Kim, C. Obasaju, M. Socinski, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients

R. Abrams, M. Liptay, W. Warren, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.